Single-arm phase II study: EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.
24 Jun, 2022 | 10:49h | UTCEZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)